Safety of lacto‐N‐triose II as a novel food pursuant to Regulation (EU) 2015/2283
EFSA Journal · 01.07.2026 · 24 (7) · e10257-e10257
DOI: 10.2903/j.efsa.2026.10257 ↗Kurz gefasst
Fachartikel in der Zeitschrift EFSA Journal, erschienen am 01.07.2026. Verfasst von EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA) und 24 weiteren Autor:innen. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Following a request from the European Commission, the EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA) was asked to deliver an opinion on lacto‐N‐triose II (LNTri II) as a novel food (NF) pursuant to Regulation (EU) 2015/2283. The NF is mainly composed of the human‐identical milk oligosaccharide (HiMO) LNTri II, but it also contains d‐glucose, d‐galactose, d‐lactose and lacto‐N‐triitol. The NF is produced by fermentation with a genetically modified strain (Kluyveromyces lactis DSM 709‐2‐02) of K. lactis DSM 70799. The information on the identity, production process, composition and specifications of the NF does not raise safety concerns. The applicant intends to add the NF in a variety of foods, including infant formula (IF), follow‐on formula (FOF), food supplements (FS) and food for special medical purposes (FSMP). The target population is the general population. In line with other HiMOs, the safety assessment of this NF is mainly based on the comparison between the intake of breastfed infants and the estimated intake of the NF. The anticipated daily intake from its use in IF is similar to the estimated natural mean highest daily intake in breastfed infants. The anticipated daily intake from the NF as a food ingredient at the maximum proposed use levels exceeds the intake level of breastfed infants on a body weight basis in infants and children. Of note, higher exposure can be obtained from LNTri II as it is a by‐product in the already authorised HiMOs (e.g. Lacto‐N‐tetraose). In addition, the natural intake estimate does not consider the formation of LNTri II at gastrointestinal level by gut microbiota fermentation or acid hydrolysis. The Panel considers that the consumption of the NF at the proposed uses and use levels does not raise safety concerns and concludes that the NF is safe under the proposed conditions of use.
Schlagwörter
Stichwörter der Autor:innen
Zitieren
APA
EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA), Turck, D., Bohn, T., Cámara, M., Castenmiller, J., De Henauw, S., Jos, Á., Maciuk, A., Mangelsdorf, I., McNulty, B., Naska, A., Pentieva, K., Siani, A., Thies, F., Aguilera-Gómez, M., Frenzel, T., Cámara, M., Mangelsdorf, I., Marcon, F., …, & Hirsch-Ernst, K. I. (2026). Safety of lacto‐N‐triose II as a novel food pursuant to Regulation (EU) 2015/2283. EFSA Journal, 24(7), e10257-e10257. https://doi.org/10.2903/j.efsa.2026.10257
Vancouver
EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA), Turck D, Bohn T, Cámara M, Castenmiller J, De Henauw S, et al. Safety of lacto‐N‐triose II as a novel food pursuant to Regulation (EU) 2015/2283. EFSA Journal. 2026;24(7):e10257-e10257. doi:10.2903/j.efsa.2026.10257
BibTeX
@article{EFSAPanelonNutritionNovelFoodsandFoodAllergensNDA2026,
author = {EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA), EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA) and Turck, Dominique and Bohn, Torsten and Cámara, Montaña and Castenmiller, Jacqueline and De Henauw, Stefaan and Jos, Ángeles and Maciuk, Alexandre and Mangelsdorf, Inge and McNulty, Breige and Naska, Androniki and Pentieva, Kristina and Siani, Alfonso and Thies, Frank and Aguilera-Gómez, Margarita and Frenzel, Thomas and Cámara, Montaña and Mangelsdorf, Inge and Marcon, Francesca and McArdle, Harry J and Moldeus, Peter and Neuhäuser-Berthold, Monika and Noriega Fernández, Estefanía and Ropero-Pérez, Carolina and Hirsch-Ernst, Karen Ildico},
title = {Safety of lacto‐N‐triose II as a novel food pursuant to Regulation (EU) 2015/2283},
journal = {EFSA Journal},
year = {2026},
volume = {24},
number = {7},
pages = {e10257--e10257},
doi = {10.2903/j.efsa.2026.10257}
}
EUVIMED